145 related articles for article (PubMed ID: 35223993)
1. ROS-Induced DCTPP1 Upregulation Contributes to Cisplatin Resistance in Ovarian Cancer.
Wang Y; Chen P; Chen X; Gong D; Wu Y; Huang L; Chen Y
Front Mol Biosci; 2022; 9():838006. PubMed ID: 35223993
[TBL] [Abstract][Full Text] [Related]
2. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
[TBL] [Abstract][Full Text] [Related]
3. Human dCTP pyrophosphatase 1 promotes breast cancer cell growth and stemness through the modulation on 5-methyl-dCTP metabolism and global hypomethylation.
Song FF; Xia LL; Ji P; Tang YB; Huang ZM; Zhu L; Zhang J; Wang JQ; Zhao GP; Ge HL; Zhang Y; Wang Y
Oncogenesis; 2015 Jun; 4(6):e159. PubMed ID: 26075750
[TBL] [Abstract][Full Text] [Related]
4. ROS-Induced SIRT2 Upregulation Contributes to Cisplatin Sensitivity in Ovarian Cancer.
Wang W; Im J; Kim S; Jang S; Han Y; Yang KM; Kim SJ; Dhanasekaran DN; Song YS
Antioxidants (Basel); 2020 Nov; 9(11):. PubMed ID: 33207824
[TBL] [Abstract][Full Text] [Related]
5. DCTPP1, an Oncogene Regulated by miR-378a-3p, Promotes Proliferation of Breast Cancer via DNA Repair Signaling Pathway.
Niu M; Shan M; Liu Y; Song Y; Han JG; Sun S; Liang XS; Zhang GQ
Front Oncol; 2021; 11():641931. PubMed ID: 34113564
[TBL] [Abstract][Full Text] [Related]
6. The NTP pyrophosphatase DCTPP1 contributes to the homoeostasis and cleansing of the dNTP pool in human cells.
Requena CE; Pérez-Moreno G; Ruiz-Pérez LM; Vidal AE; González-Pacanowska D
Biochem J; 2014 Apr; 459(1):171-80. PubMed ID: 24467396
[TBL] [Abstract][Full Text] [Related]
7. DCTPP1 prevents a mutator phenotype through the modulation of dCTP, dTTP and dUTP pools.
Martínez-Arribas B; Requena CE; Pérez-Moreno G; Ruíz-Pérez LM; Vidal AE; González-Pacanowska D
Cell Mol Life Sci; 2020 Apr; 77(8):1645-1660. PubMed ID: 31377845
[TBL] [Abstract][Full Text] [Related]
8. Targeting ACLY Attenuates Tumor Growth and Acquired Cisplatin Resistance in Ovarian Cancer by Inhibiting the PI3K-AKT Pathway and Activating the AMPK-ROS Pathway.
Wei X; Shi J; Lin Q; Ma X; Pang Y; Mao H; Li R; Lu W; Wang Y; Liu P
Front Oncol; 2021; 11():642229. PubMed ID: 33816292
[No Abstract] [Full Text] [Related]
9. Autophagy induced by overexpression of DCTPP1 promotes tumor progression and predicts poor clinical outcome in prostate cancer.
Lu J; Dong W; He H; Han Z; Zhuo Y; Mo R; Liang Y; Zhu J; Li R; Qu H; Zhang L; Wang S; Ma R; Jia Z; Zhong W
Int J Biol Macromol; 2018 Oct; 118(Pt A):599-609. PubMed ID: 29874556
[TBL] [Abstract][Full Text] [Related]
10. The nucleotidohydrolases DCTPP1 and dUTPase are involved in the cellular response to decitabine.
Requena CE; Pérez-Moreno G; Horváth A; Vértessy BG; Ruiz-Pérez LM; González-Pacanowska D; Vidal AE
Biochem J; 2016 Sep; 473(17):2635-43. PubMed ID: 27325794
[TBL] [Abstract][Full Text] [Related]
11. Silencing DSCAM-AS1 suppresses the growth and invasion of ER-positive breast cancer cells by downregulating both DCTPP1 and QPRT.
Yue Z; Shusheng J; Hongtao S; Shu Z; Lan H; Qingyuan Z; Shaoqiang C; Yuanxi H
Aging (Albany NY); 2020 Jul; 12(14):14754-14774. PubMed ID: 32716908
[TBL] [Abstract][Full Text] [Related]
12. Direct impact of cisplatin on mitochondria induces ROS production that dictates cell fate of ovarian cancer cells.
Kleih M; Böpple K; Dong M; Gaißler A; Heine S; Olayioye MA; Aulitzky WE; Essmann F
Cell Death Dis; 2019 Nov; 10(11):851. PubMed ID: 31699970
[TBL] [Abstract][Full Text] [Related]
13. A reactive oxygen species scoring system predicts cisplatin sensitivity and prognosis in ovarian cancer patients.
Sun C; Guo E; Zhou B; Shan W; Huang J; Weng D; Wu P; Wang C; Wang S; Zhang W; Gao Q; Xu X; Wang B; Hu J; Ma D; Chen G
BMC Cancer; 2019 Nov; 19(1):1061. PubMed ID: 31703584
[TBL] [Abstract][Full Text] [Related]
14. Phosphorylation of eIF2α suppresses cisplatin-induced p53 activation and apoptosis by attenuating oxidative stress via ATF4-mediated HO-1 expression in human renal proximal tubular cells.
Ju SM; Jo YS; Jeon YM; Pae HO; Kang DG; Lee HS; Bae JS; Jeon BH
Int J Mol Med; 2017 Dec; 40(6):1957-1964. PubMed ID: 29039478
[TBL] [Abstract][Full Text] [Related]
15. DUOXA1-mediated ROS production promotes cisplatin resistance by activating ATR-Chk1 pathway in ovarian cancer.
Meng Y; Chen CW; Yung MMH; Sun W; Sun J; Li Z; Li J; Li Z; Zhou W; Liu SS; Cheung ANY; Ngan HYS; Braisted JC; Kai Y; Peng W; Tzatsos A; Li Y; Dai Z; Zheng W; Chan DW; Zhu W
Cancer Lett; 2018 Aug; 428():104-116. PubMed ID: 29704517
[TBL] [Abstract][Full Text] [Related]
16. Cisplatin resistance in human cervical, ovarian and lung cancer cells.
Chen J; Solomides C; Parekh H; Simpkins F; Simpkins H
Cancer Chemother Pharmacol; 2015 Jun; 75(6):1217-27. PubMed ID: 25894720
[TBL] [Abstract][Full Text] [Related]
17. Gallic acid induces apoptosis and enhances the anticancer effects of cisplatin in human small cell lung cancer H446 cell line via the ROS-dependent mitochondrial apoptotic pathway.
Wang R; Ma L; Weng D; Yao J; Liu X; Jin F
Oncol Rep; 2016 May; 35(5):3075-83. PubMed ID: 26987028
[TBL] [Abstract][Full Text] [Related]
18. Zinc Finger Protein 90 Knockdown Promotes Cisplatin Sensitivity via Nrf2/HO-1 Pathway in Ovarian Cancer Cell.
Wu CH; Feng CW; Wang CL; Wen ZH; Long CY; Tang FH
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900383
[TBL] [Abstract][Full Text] [Related]
19. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function.
Fraser M; Bai T; Tsang BK
Int J Cancer; 2008 Feb; 122(3):534-46. PubMed ID: 17918180
[TBL] [Abstract][Full Text] [Related]
20. Loss of Scribble confers cisplatin resistance during NSCLC chemotherapy via Nox2/ROS and Nrf2/PD-L1 signaling.
Wang N; Song L; Xu Y; Zhang L; Wu Y; Guo J; Ji W; Li L; Zhao J; Zhang X; Zhan L
EBioMedicine; 2019 Sep; 47():65-77. PubMed ID: 31495720
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
